d-alpha tocopherol has been researched along with Fatty Liver, Nonalcoholic in 196 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (0.51) | 29.6817 |
| 2010's | 140 (71.43) | 24.3611 |
| 2020's | 55 (28.06) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Cui, H; Li, L; Li, X; Li, Z; Ma, X; Tang, Z; Wang, C; Wu, B; Zheng, X | 1 |
| Aamir, M; Khan, DA; Mirza, SA; Nisar, U; Pervez, MA; Slehria, AUR | 1 |
| Demirel-Yalciner, T; Ozer, NK; Sari, D; Sozen, E | 1 |
| Fatima, S; Gilani, STA; Ijaz, A; Khan, DA; Nida, S; Pervez, MA | 1 |
| Chew, DCH; Chin, KY; Ekeuku, SO; Trias, A | 1 |
| Bianchini, C; D'Ambrosio, R; Di Cesare Mannelli, L; Ghelardini, C; Lampertico, P; Micheli, L; Pacini, A; Trallori, E | 1 |
| Jeon, D; Shim, J; Son, M | 1 |
| Demirel-Yalciner, T; Ozaltin, E; Ozer, NK; Sahin, A; Sozen, E | 1 |
| Barola, C; Bartolini, D; Bellezza, G; Galarini, R; Galli, F; Giusepponi, D; Russo, A; Rychlicki, C; Sidoni, A; Svegliati-Baroni, G; Torquato, P | 1 |
| Borggrefe, J; Both, M; di Giuseppe, R; Esatbeyoglu, T; Jacobs, G; Kassubek, J; Koch, M; Lieb, W; Müller, HP; Nöthlings, U; Plachta-Danielzik, S; Ratjen, I; Rimbach, G; Schlesinger, S; Waniek, S | 1 |
| Bartolini, D; Galarini, R; Galli, F; Giusepponi, D; Piroddi, M; Saluti, G; Sebastiani, B; Torquato, P | 1 |
| Abu Bakar, MR; Ansari, MA; Gopalan, Y; Khan, NA; Magosso, E; Ng, BH; Shuaib, IL; Wong, JW; Yuen, KH | 1 |
| Athinarayanan, S; Bai, S; Chalasani, N; Cummings, OW; Liu, W; Molleston, J; Traber, MG; Wei, R; Yates, K; Zhang, M | 1 |
| Pashkov, AN; Popov, SS; Shul'gin, KK | 1 |
| Bruno, RS; Chung, MY; Park, HJ; Volek, JS; Yeung, SF | 1 |
| Ahmadi-Juoibari, T; Aneva, IY; Ataee, M; Bahrami, G; Farzaei, MH; Heydarpour, F; Majnooni, MB | 1 |
| Fujii, H; Hara, N; Itoh, Y; Nakajima, A; Okanoue, T; Seko, Y; Sumida, Y; Takahashi, H; Yoneda, M | 1 |
| Kohli, R; Mitsinikos, T; Mrowczynski-Hernandez, P | 1 |
| Abdelaziz, AE; Abdelkawy, KS; Ali, AA; Elbarbry, F; Fouda, A; Hussien, M | 1 |
| Chen, B; Gao, F; Gu, Y; Liu, P; Liu, Q; Liu, W; Wu, P; Xiao, Y; Xie, W | 1 |
| Graham, Y; Kassir, R; Leal, A; Mahawar, K; Pintar, T; Pouwels, S; Ramnarain, D; Sakran, N; Singhal, R; Yang, W | 1 |
| Creasy, KT; Rader, DJ; Schneider, CV; Schneider, KM; Scorletti, E; Vell, M; Vujkovic, M; Zandvakili, I | 1 |
| Aveyard, P; Cobbold, JF; Heath, L; Koutoukidis, DA; Tomlinson, JW | 1 |
| Cammà, C; Celsa, C; Ciccioli, C; Craxì, A; Di Marco, V; Enea, M; Infantino, G; La Mantia, C; Parisi, S; Pennisi, G; Petta, S; Vaccaro, M; Vernuccio, F | 1 |
| Alisi, A; Bianchi, M; Braghini, MR; Comparcola, D; Condorelli, AG; Conti, LA; Crudele, A; De Stefanis, C; Gurrado, F; Lioci, G; Mosca, A; Nobili, R; Panera, N; Sartorelli, MR; Scoppola, V; Smeriglio, A; Svegliati-Baroni, G; Trombetta, D | 1 |
| Chommaitree, P; Kritsanaviparkporn, C; Poonyam, P; Soodcharoen, A | 1 |
| Breder, VV; Doshchitsin, VL; Dudinskaya, EN; Ershova, EV; Geyvandova, NI; Ivashkin, VT; Kodzoeva, KB; Komshilova, KA; Korochanskaya, NV; Kotovskaya, YV; Maevskaya, MV; Mayorov, AY; Mishina, EE; Nadinskaya, MY; Nikitin, IG; Pogosova, NV; Shamkhalova, MS; Shestakova, MV; Tarzimanova, AI; Tkacheva, ON; Troshina, EA | 1 |
| Alexander, L; Behling, C; Biegel, H; Chalasani, N; Dasarathy, S; Diehl, AM; Hameed, B; Jia, Y; Karpen, SJ; Kleiner, DE; Kowdley, KV; Lavine, JE; Loomba, R; Neuschwander-Tetri, BA; Ostroff, R; Sanyal, AJ; Tonascia, J; Williams, J; Williams, SA; Yates, KP | 1 |
| Álvares-da-Silva, MR; Behrens, L; Cerski, CT; de Freitas, LBR; de Souza, VEG; Filippi-Chiela, E; Leonhard, LC; Lima, GJSP; Longo, L; Luchese, E; Pereira, MHM; Pinzon, CE; Uribe-Cruz, C; Zanettini, G | 1 |
| Eidi, A; Lahmi, A; Oryan, S; Rohani, AH | 1 |
| Chen, Y; Deng, C; Gu, Y; He, Y; Kong, T; Li, J; Shi, J; Sun, L; Yang, L; Zhang, W; Zhou, R | 1 |
| Beheshtirouy, S; Gharekhani, A; Khoshbaten, M; Rezaee, H; Shayanrad, S | 1 |
| Bueno, AA; da Silva Sassaki, B; de Avelar, CR; de Jesus, RP; de Oliveira, LPM; Dos Santos Vasconcelos, M; Lyra, AC; Nunes, BVC | 1 |
| Bai, Y; Chen, Y; Ju, S; Li, T; Liu, J; Wang, C; Wang, Y; Xiong, B; Yao, W; Zhou, C | 1 |
| Arasteh, A; Graham, DS; Liu, G; Yan, S; Yin, XM | 1 |
| Amanullah, I; Anwar, I; Gulzar, A; Khan, YH; Mallhi, TH; Raja, AA | 1 |
| Kim, KI; Kim, SK; Kim, SR | 1 |
| Hawa, G; Jungwirth, T; Karabouta, Z; Kountouras, J; Polyzos, SA | 1 |
| de Pokomandy, A; Deschenes, M; Ghali, P; Haraoui, LP; Klein, M; Lebouche, B; Routy, JP; Saeed, S; Sebastiani, G; Szabo, J; Wong, P | 1 |
| Cossiga, V; Dallio, M; Di Sarno, R; Federico, A; Gravina, AG; Lama, S; Loguercio, C; Masarone, M; Morisco, F; Persico, M; Stiuso, P; Tuccillo, C | 1 |
| Ipsen, DH; Klaebel, JH; Lykkesfeldt, J; Rakipovski, G; Schou-Pedersen, AMV; Skat-Rørdam, J; Skjødt, M; Tveden-Nyborg, P | 1 |
| Guaraldi, G; Milic, J | 1 |
| Arce-Clachar, AC; Bramlage, K; Fei, L; Mouzaki, M; Orkin, S; Su, W; Xanthakos, SA; Yodoshi, T | 1 |
| Nakajima, A; Ogawa, Y; Okanoue, T; Sumida, Y; Yoneda, M | 1 |
| Chi, X; DeBoer, MD; Gurka, MJ; Mack, JA | 1 |
| Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A | 1 |
| Börmel, L; Lorkowski, S; Wallert, M | 1 |
| Antza, C; Bakaloudi, DR; Chourdakis, M; Dardavessis, T; Doundoulakis, I; Kalopitas, G; Maris, T; Samara, M; Vadarlis, A | 1 |
| Kohli, R; Lin, CH | 1 |
| Chung, JY; Hewitt, SM; Kleiner, DE; Podszun, MC; Rotman, Y; Ylaya, K | 1 |
| Alawad, AS; Cai, H; Fatima, SZ; Garraffo, HM; Gharib, AM; Huang, WA; Kleiner, DE; Levine, M; Lin, DD; Lingala, S; Ma, Y; Mahajan, LS; Morris, N; Ouwerkerk, R; Podszun, MC; Rolt, A; Rotman, Y; Samala, N; Schoenfeld, M; Shamburek, R; Umarova, R; Valdez, K; Violet, PC; Walter, PJ; Yang, S | 1 |
| Ijaz, A; Khan, DA; Pervez, MA; Slehria, AUR | 1 |
| Alisi, A; Alterio, A; Braghini, MR; Comparcola, D; Crudele, A; Mosca, A; Panera, N; Raponi, M; Sartorelli, MR; Smeriglio, A; Tozzi, G; Trombetta, D | 1 |
| Cuozzo, S; Curcio, A; Grassi, O; Nicola, AD; Nocera, GF; Pironti, M; Romano, A; Schiaroli, D | 1 |
| Bader, AR; Jeske, R; Westfall, E | 1 |
| Alberti, G; Gana, JC; Santos, JL | 1 |
| Deng, G; Lei, J; Li, J; Lin, M; Zeng, H | 1 |
| Kalogerinis, CT; Kalogerinis, PT; Milanov, V; Poulos, EJ; Poulos, JE | 1 |
| Bhardwaj, A; Bihari, C; Kedarisetty, CK; Kumar, G; Kumar, M; Rastogi, A; Sarin, SK | 1 |
| Classen, HG; Eckert, GP; Egert, S; Frank, J; Golombek, J; Kisters, K; Lorkowski, S; Obeid, R; Pettersen, JA; Podszun, MC; Stirban, OA; Venturelli, S; Wallert, M | 1 |
| Frank, J; Podszun, MC | 1 |
| Abdelmalek, MF; Diehl, AM; Guy, CD; Henao, R; Howe, C; Moylan, CA; Wang, Y; Wegermann, K | 1 |
| Chen, XM; Lv, BD; Ru, QJ; Sun, T; Zhang, B | 1 |
| Seen, S | 1 |
| Chalasani, N; Cummings, OW; Gawrieh, S; Harlow, KE; Molleston, JP; Pike, F; Rosenberg, WM; Wilson, LA; Yates, KP | 1 |
| Barnard, A; Dave, S; Loomba, R; Majzoub, AM; Munaganuru, N; Murad, MH; Nayfeh, T; Singh, S | 1 |
| Kamath, BM; Ling, SC; Mouzaki, M; Schreiber, RA | 1 |
| Banini, BA; Sanyal, AJ | 2 |
| Katsinelos, P; Kountouras, J; Mantzoros, CS; Polymerou, V; Polyzos, SA | 1 |
| Li, C; Xu, Y | 1 |
| Chen, G; Kaneko, S; Kobori, M; Nagashimada, M; Ni, Y; Ota, T; Sakurai, M; Takahashi, Y | 2 |
| Caldwell, S | 1 |
| Fleet, SE; Lavine, JE; Lefkowitch, JH | 1 |
| Alisi, A; Crudele, A; Della Corte, C; Fauler, G; Jahnel, J; Mosca, A; Nobili, V; Zöhrer, E | 1 |
| Newsome, PN; Townsend, SA | 1 |
| Chan, HL; Chan, WK; Chawla, Y; Chitturi, S; Dan, YY; Duseja, A; Fan, J; Farrell, G; Goh, KL; Hamaguchi, M; Hashimoto, E; Kim, SU; Lesmana, LA; Lin, YC; Liu, CJ; Ni, YH; Sollano, J; Wong, GL; Wong, SK; Wong, VW | 1 |
| Allen, L; Chung, E; Dufour, JM; Kalupahana, NS; Kaur, G; Menikdiwela, K; Moustaid-Moussa, N; Ramalingam, L; Scoggin, S; Shen, CL; Tomison, MD | 1 |
| Bush, H; Golabi, P; Younossi, ZM | 1 |
| Alcala, M; Calderon-Dominguez, M; Herrero, L; Ramos, MP; Serra, D; Viana, M | 1 |
| Adinolfi, LE; Lonardo, A; Marrazzo, A; Maurantonio, M; Nascimbeni, F; Rinaldi, L | 1 |
| Mao, YM; Tang, JT | 1 |
| Cheng, ER; Gillman, MW; Oken, E; Rifas-Shiman, SL; Taveras, EM; Woo Baidal, JA | 1 |
| Armengol, L; Arola, L; Caimari, A; Maria Del Bas, J; Mariné, S; Moriña, D; Puiggròs, F; Rodríguez, B; Rodríguez, MA | 1 |
| Abbas, AM; Haidara, MA; Sakr, HF | 1 |
| Boniecka, I; Czerwonogrodzka-Senczyna, A; Ostrowska, J; Sarosiekjeznach-Steinhagen, A | 1 |
| Bai, L; Chen, J; Chi, X; He, F; Sheng, H; Shi, J; Song, Y; Wang, B; Wang, J; Xie, S; Xie, W; Yang, Y; Zang, S; Zhang, J; Zheng, M; Zou, Z | 1 |
| Issa, D; Patel, V; Sanyal, AJ | 1 |
| Alkhouri, N; Conjeevaram Selvakumar, PK; Kabbany, MN | 1 |
| Ijaz, A; Khan, DA; Khan, S; Pervez, MA | 1 |
| Aller, R; de Luis, D; Durà, M; García Sánchez, C; Izaola, O; Laserna, C; Mora, N; Pina, M; Primo, D; Rojo, MÁ; Sigüenza, R | 1 |
| Adachi, T; Okada, H; Takaki, A; Uchida, D | 1 |
| Grønbæk, H; Heebøll, S; Vilstrup, H | 1 |
| Kumar, RB; Mathews, SE; Shukla, AP | 1 |
| Bellentani, S; Cicero, AFG; Colletti, A | 1 |
| Chung, S; Kim, Y; Natarajan, SK | 1 |
| Donnelly, PE | 1 |
| Elamin, A; Sequeira, RP; Sivaramakrishnan, G; Sridharan, K | 1 |
| Honda, Y; Imajo, K; Kessoku, T; Kobayashi, T; Nakajima, A; Ogawa, Y; Saito, S; Yoneda, M | 1 |
| Chaiyakunapruk, N; Chongmelaxme, B; Dilokthornsakul, P; Phisalprapa, P; Sawangjit, R | 1 |
| Anastasilakis, AD; Doulberis, M; Hawa, G; Katsinelos, P; Kountouras, J; Makras, P; Missbichler, A; Polyzos, SA; Sonnleitner, L; Terpos, E | 1 |
| Chalasani, N; Cummings, OW; Gawrieh, S; Ghabril, M; Saxena, R; Vilar-Gomez, E; Vuppalanchi, R | 1 |
| Brunt, EM; Kleiner, DE; Neuschwander-Tetri, BA; Sanyal, AJ; Wilson, LA | 1 |
| Gorard, DA; Julai, A; Tanner, S | 1 |
| Alekhina, LM; Chumak, AA; Gasanova, EO; Nosach, OV; Ovsyannikova, LM; Sarkisova, EA; Shyiko, TO | 1 |
| Amirkhizi, F; Ebrahimi-Mameghani, M; Hosseinpour-Arjmand, S | 1 |
| Alisi, A; Crudele, A; Denaro, M; Mosca, A; Nobili, V; Smeriglio, A; Trombetta, D; Zaffina, S | 1 |
| Nagashimada, M; Ota, T | 1 |
| Alisi, A; Bartolini, D; Cruciani, G; Crudele, A; Di Veroli, A; Galarini, R; Galli, F; Giusepponi, D; Goracci, L; Nobili, V; Piroddi, M; Torquato, P | 1 |
| Cheung, A; Figueredo, C; Rinella, ME | 1 |
| Shetty, A; Syn, WK | 1 |
| Chalasani, N; Vilar-Gomez, E | 1 |
| Altinbas, A; Chalasani, N; Chung, RT; Corey, KE; Kleiner, DE; Krauss, RM; Wilson, LA; Yates, KP | 1 |
| He, J; Leng, AM | 1 |
| Anushiravani, A; Haddadi, N; Mohammadkarimi, V; Pourfarmanbar, M | 1 |
| Brunner, KT; Henneberg, CJ; Long, MT; Wilechansky, RM | 1 |
| He, W; Lei, K; Liu, D; Ren, X; Xiang, D; Xu, Y; Zhang, C | 1 |
| Byrne, CD; Jennison, E; Patel, J; Scorletti, E | 1 |
| Barbakadze, G; Burnadze, K; Jebashvili, M; Khachidze, T; Sulaberidze, G | 1 |
| Bottomley, J; Jiandani, NR; Oliver, L; Perry, R; Povsic, M | 1 |
| Al-Hamoudi, WK; Al-Judaibi, B; Al-Osaimi, A; Alswat, KA; Alturaify, N; Elsiesy, HA; Fallatah, HI; Qutub, AN | 1 |
| Fliss-Isakov, N; Ivancovsky-Wajcman, D; Kariv, R; Salomone, F; Shibolet, O; Webb, M; Zelber-Sagi, S | 1 |
| Biernacki, DM; Bril, F; Cusi, K; Hecht, J; Kalavalapalli, S; Lai, J; Lomonaco, R; Orsak, BK; Subbarayan, SK; Suman, A; Tio, F | 1 |
| Clark, JM; Hoofnagle, JH; Kleiner, DE; Kowdley, KV; Loomba, R; Neuschwander-Tetri, BA; Sanyal, AJ; Tonascia, J; Van Natta, ML | 1 |
| Inada, Y; Itoh, Y; Kanemasa, K; Naito, Y; Okanoue, T; Sakai, K; Sumida, Y; Taketani, H; Tanaka, S; Yasui, K; Yoshikawa, T | 1 |
| Ding, XD; Fan, JG; Han, Y; Ma, AL; Shi, JP; Xu, Y | 1 |
| Henry, L; Mehta, R; Mishra, A; Reyes, MJ; Younossi, ZM | 1 |
| Allard, JP; Arendt, BM; Da Silva, HE; Guindi, M; Noureldin, SA; Therapondos, G | 1 |
| Loomba, R; Pearlman, M | 1 |
| Abdelmalek, MF; Burchette, JL; Diehl, AM; Guy, CD; Suzuki, A | 1 |
| Gores, GJ; Hirsova, P | 1 |
| Ji, HF; Shen, L; Sun, Y | 1 |
| Abdelmalek, M; Burchette, J; Diehl, AM; Guy, C; Suzuki, A | 1 |
| Grzelak, CA; McCaughan, GW; Sigglekow, ND | 1 |
| Lavine, JE; Mitchel, EB | 1 |
| Chalasani, N; Corey, KE; Cummings, OW; Vuppalanchi, R; Wilson, LA | 1 |
| Abenavoli, L; Accattato, F; Foti, D; Greco, M; Gulletta, E; Luzza, F; Milic, N; Nazionale, I; Peta, V | 1 |
| Hashimoto, E; Ikejima, K; Mizuta, T; Nakajima, A; Nakamuta, M; Ono, M; Saibara, T; Sakaida, I; Seike, M; Shimosegawa, T; Shiota, G; Sugano, K; Sumida, Y; Takehara, T; Takei, Y; Tokushige, K; Tsubouchi, H; Uto, H; Watanabe, S; Yoneda, M | 1 |
| Coppola, D; Crispino, P; De Stefano, G; Sorrentino, G | 1 |
| Anstee, QM; Day, CP; Hardy, T | 1 |
| Hasegawa, T; Sato, K; Yoneda, M | 1 |
| Ji, HF | 1 |
| Rinella, ME | 1 |
| Halilbasic, E; Hofer, H; Kazemi-Shirazi, L; Kienbacher, C; Munda, P; Rechling, C; Trauner, M; Traussnigg, S | 1 |
| Allen, AM; Khera, R; Loomba, R; Murad, MH; Singh, S | 1 |
| Argo, CK; Caldwell, SH; Ikura, Y; Lackner, C | 1 |
| Diehl, AM; Guy, CD | 1 |
| Ahmed, A; Harrison, SA; Wong, RJ | 1 |
| Aller, R; Berroa, E; de Luis, DA; Gómez, S; González, G; González, JM; Izaola, O; Mora, N; Tafur, C | 1 |
| Yki-Järvinen, H | 1 |
| Berretta, M; Di Benedetto, F; Di Francia, R; Rinaldi, L; Troisi, A | 1 |
| Aller, R; de Luis, DA | 1 |
| Bomfati, F; Karimian, G; Kirschbaum, M; Lisman, T; Porte, RJ; Veldhuis, ZJ | 1 |
| Kaneko, S; Nagashimada, M; Nagata, N; Nakanuma, Y; Ni, Y; Ota, T; Tsutsui, A; Zhan, L; Zhuge, F | 1 |
| Antommaria, AH; Bramlage, KS | 1 |
| Chung, JW; Hwang, JH; Jang, ES; Jeong, SH; Kim, GH; Kim, J; Kim, JW; Kim, N; Lee, DH; Lee, JH; Ok, KS; Park, YS; Shin, CM | 1 |
| Klyarytskaya, IL; Maksymova, EV; Stilidi, EI | 1 |
| Corey, KE; Rinella, ME | 1 |
| Ganesh, S; Rustgi, VK | 1 |
| Charlton, MR; Dick, TB; Pham, T | 1 |
| Fietto, LG; Freitas, RB; Gonçalves, RV; Leite, JP; Lima, LM; Mendonça, BG; Novaes, RD; Peluzio, Mdo C; Ribeiro, AQ; Santos, EC | 1 |
| Atay, K; Canbakan, B; Dobrucalı, A; Gültepe, I; Hatemi, İ; Köroğlu, E; Şentürk, H; Sonsuz, A; Tuncer, M | 1 |
| Chaiyakunapruk, N; Chongmelaxme, B; Kowdley, KV; Phisalprapa, P; Saokaew, S; Sawangjit, R; Thakkinstian, A | 1 |
| Chen, G; Nagata, N; Ni, Y; Ota, T; Xu, L | 1 |
| Mintziori, G; Polyzos, SA | 1 |
| Abedi, R; Ebrahimi-Mameghani, M; Jamali, H; Kabir-Mamdooh, B; Kakaei, F; Mahdavi, R | 1 |
| Dufour, JF; Perazzo, H | 1 |
| Jun, DW; Nguyen, MH; Oh, H; Saeed, WK | 1 |
| Oseini, AM; Sanyal, AJ | 1 |
| Ji, HF; Shen, L | 1 |
| Carani Venkatraman, A; Mohamed Salih, S; Muniyandi, P; Nallasamy, P; Periyasami, V | 1 |
| Lavine, JE; Mencin, AA | 1 |
| Álvarez Ferre, J; González Jiménez, E; Schmidt Río-Valle, J | 1 |
| Guan, X; Lin, L; Tang, Y; Wang, L | 1 |
| Deretzi, G; Katsiki, E; Kountouras, J; Patsiaoura, K; Polyzos, SA; Rakitzi, P; Slavakis, A; Tsarouchas, G; Zafeiriadou, E; Zavos, C | 1 |
| Adinolfi, LE; Restivo, L | 1 |
| Bellentani, S; Lonardo, A; Loria, P; Ratziu, V | 1 |
| Abrams, SH; Brunt, EM; Chalasani, N; Clark, JM; Hoofnagle, JH; Kleiner, DE; Lavine, JE; Molleston, JP; Murray, KF; Robuck, PR; Rosenthal, P; Sanyal, AJ; Scheimann, AO; Schwimmer, JB; Tonascia, J; Ünalp, A; Van Natta, ML | 1 |
| Adams, LA; Smith, BW | 1 |
| Alisi, A; Nobili, V | 1 |
| Mullin, GE | 1 |
| Andrews, DB; Lavine, JE | 1 |
| Dumortier, J; Guillaud, O; Hervieu, V; Pietu, F; Scoazec, JY; Vallin, M; Walter, T | 1 |
| Belt, P; Colvin, R; Lavine, JE; Molleston, JP; Murray, KF; Rosenthal, P; Schwimmer, JB; Tonascia, J; Unalp, A; Vos, MB | 1 |
| Brunt, EM; Chalasani, N; Charlton, M; Cusi, K; Diehl, AM; Lavine, JE; Sanyal, AJ; Younossi, Z | 2 |
| Bass, NM; Bell, LN; Brunt, EM; Chalasani, N; Chalasani, S; Diehl, AM; Fullenkamp, AM; Kowdley, KV; McCullough, AJ; Muralidharan, S; Neuschwander-Tetri, BA; Sanyal, AJ; Unalp-Arida, A; Wang, J; Wilson, LA | 1 |
| Akcam, M; Boyaci, A; Dundar, BN; Kaya, S; Pirgon, O; Uysal, S | 1 |
| Craig, JC; George, J; Mahady, SE; Wong, G | 1 |
| Aouizerat, B; Cheng, J; Joyce, A; Sanyal, AJ; Yates, K | 1 |
| Pacana, T; Sanyal, AJ | 1 |
| Beiraghdar, F; Ghamarchehreh, ME; Jalalian, HR; Panahi, Y; Sahebkar, A; Zare, R | 1 |
| Bril, F; Cusi, K; Lomonaco, R; Sunny, NE | 1 |
69 review(s) available for d-alpha tocopherol and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review.
Topics: alpha-Tocopherol; Animals; Humans; Liver; Non-alcoholic Fatty Liver Disease; Tocotrienols; Vitamin E | 2023 |
Pediatric Nonalcoholic Fatty Liver Disease.
Topics: Adolescent; Alanine Transaminase; Child; Child, Preschool; Diet Therapy; Elasticity Imaging Techniques; Exercise; Female; Humans; Liver; Liver Transplantation; Male; Non-alcoholic Fatty Liver Disease; Obesity; Risk Factors; Ultrasonography; Vitamin E; Young Adult | 2021 |
Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.
Topics: Diet Therapy; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Vitamin E; Weight Loss | 2022 |
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis.
Topics: Drugs, Investigational; Humans; Liver; Liver Cirrhosis; Network Meta-Analysis; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Vitamin E | 2022 |
The Effects of Combined Vitamin E and C for Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Adult; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Child; Humans; Liver; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Vitamin E; Vitamins | 2022 |
Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled tria
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Necrosis; Network Meta-Analysis; Non-alcoholic Fatty Liver Disease; Pilot Projects; Pioglitazone; Randomized Controlled Trials as Topic; Vitamin E | 2023 |
Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials.
Topics: Humans; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Treatment Outcome; Vitamin E; Vitamins | 2019 |
[Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
Topics: Diagnosis, Differential; Diet Therapy; Exercise Therapy; Female; Humans; Life Style; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Prognosis; Vitamin E | 2019 |
Current and new pharmacotherapy options for non-alcoholic steatohepatitis.
Topics: Chenodeoxycholic Acid; Clinical Trials as Topic; Fibroblast Growth Factors; Glucagon-Like Peptides; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Vitamin E | 2020 |
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2021 |
Inflammatory Diseases and Vitamin E-What Do We Know and Where Do We Go?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Humans; Inflammasomes; Inflammation; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Non-alcoholic Fatty Liver Disease; Vitamin E | 2021 |
Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease.
Topics: Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Blood Glucose; Cholesterol, LDL; Dietary Supplements; Humans; Leptin; Liver; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Vitamin E | 2021 |
Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease.
Topics: Adolescent; Alanine Transaminase; Antioxidants; Bariatric Surgery; Child; Child, Preschool; Cysteamine; Cystine Depleting Agents; Delayed-Action Preparations; Diet; Humans; Hypoglycemic Agents; Infant; Infant, Newborn; Life Style; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease; Pediatric Obesity; Vitamin E | 2020 |
Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease.
Topics: Child; Fatty Acids, Omega-3; Fructose; Humans; Life Style; Liver; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Randomized Controlled Trials as Topic; Vitamin E | 2020 |
Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Child; Humans; Lipids; Liver; Non-alcoholic Fatty Liver Disease; Vitamin E | 2021 |
The role of biofactors in the prevention and treatment of age-related diseases.
Topics: Aged; Cardiovascular Diseases; Dementia; Diabetes Mellitus; Dietary Fiber; Dietary Supplements; Epigenesis, Genetic; Fatty Acids, Omega-3; Folic Acid; Humans; Neoplasms; Non-alcoholic Fatty Liver Disease; Thiamine; Thioctic Acid; Vitamin D; Vitamin E | 2021 |
Impact of vitamin E on redox biomarkers in non-alcoholic fatty liver disease.
Topics: Animals; Biomarkers; Humans; Liver; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Vitamin E | 2021 |
Chronic liver disease and oxidative stress - a narrative review.
Topics: Animals; Antioxidants; Antiviral Agents; Carcinoma, Hepatocellular; Chronic Disease; Dietary Supplements; Flavonoids; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Diseases; Liver Diseases, Alcoholic; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Reactive Oxygen Species; Vitamin E | 2021 |
Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.
Topics: Biopsy; Humans; Liver Cirrhosis; Network Meta-Analysis; Non-alcoholic Fatty Liver Disease; Pioglitazone; Vitamin E | 2021 |
Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
Topics: Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; Inflammation; Liver Cirrhosis; Liver Neoplasms; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pioglitazone; Thiazolidinediones; Vitamin E | 2017 |
NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
Topics: Dietary Supplements; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease; Thiazolidinediones; Vitamin E | 2017 |
Current Concepts in Pediatric Nonalcoholic Fatty Liver Disease.
Topics: Adolescent; Antioxidants; Child; Child, Preschool; Fibrosis; Humans; Infant; Life Style; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Obesity; Prevalence; Vitamin E; Young Adult | 2017 |
Review article: new treatments in non-alcoholic fatty liver disease.
Topics: Drug Design; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; MAP Kinase Kinase Kinase 5; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones; Vitamin E | 2017 |
The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups.
Topics: Adolescent; Asia; Bariatric Surgery; Carcinoma, Hepatocellular; Chenodeoxycholic Acid; Child; Diet; Exercise; Fatty Acids, Omega-3; Gastroenterology; Humans; Liver Neoplasms; Liver Transplantation; Non-alcoholic Fatty Liver Disease; Obesity; Pacific Islands; Practice Guidelines as Topic; Risk; Systematic Reviews as Topic; Thiazolidinediones; Vitamin E | 2018 |
Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Topics: Antioxidants; Chenodeoxycholic Acid; Cholic Acids; Diet Therapy; Exercise; Free Radical Scavengers; Humans; Hypoglycemic Agents; Life Style; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Vitamin E | 2017 |
Nonalcoholic fatty liver disease: Evolving paradigms.
Topics: Biomarkers; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Diagnostic Imaging; Diet, Reducing; Dyslipidemias; Exercise Therapy; Humans; Hyperuricemia; Hypoglycemic Agents; Liver; Liver Function Tests; Liver Neoplasms; Mass Screening; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Assessment; Risk Factors; Vitamin E | 2017 |
Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.
Topics: Antioxidants; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Thiazolidinediones; Vitamin E | 2017 |
[Non-alcoholic liver disease - diagnosis and treatment].
Topics: Biopsy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Non-alcoholic Fatty Liver Disease; Vitamin E | 2017 |
Future therapy for non-alcoholic fatty liver disease.
Topics: Animals; Diet; Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; Inflammation; Life Style; Liver Cirrhosis; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Thiazolidinediones; Vitamin E | 2018 |
Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter.
Topics: Adolescent; Bariatric Surgery; Child; Diet Therapy; Humans; Metformin; Non-alcoholic Fatty Liver Disease; Prevalence; Vitamin E | 2018 |
Beneficial and Paradoxical Roles of Anti-Oxidative Nutritional Support for Non-Alcoholic Fatty Liver Disease.
Topics: Antioxidants; Carcinoma, Hepatocellular; Contraindications, Drug; End Stage Liver Disease; Humans; Liver; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Vitamin E | 2018 |
[Treatment of non-alcoholic fatty liver disease].
Topics: Bariatric Surgery; Chalcones; Chenodeoxycholic Acid; Critical Pathways; Humans; Hypoglycemic Agents; Life Style; Liraglutide; Non-alcoholic Fatty Liver Disease; Pioglitazone; Propionates; Risk Assessment; Vitamin E | 2018 |
Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
Topics: Bariatric Surgery; Chenodeoxycholic Acid; Diet; Exercise; Heart Diseases; Humans; Life Style; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Vitamin E | 2018 |
Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.
Topics: Antioxidants; Berberine; Curcumin; Dietary Supplements; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Humans; Meta-Analysis as Topic; Non-alcoholic Fatty Liver Disease; Obesity; Observational Studies as Topic; Plant Extracts; Probiotics; Randomized Controlled Trials as Topic; Resveratrol; Salvia miltiorrhiza; Silymarin; Ubiquinone; Vitamin D; Vitamin E; Xanthophylls | 2018 |
Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis.
Topics: Anticholesteremic Agents; Antioxidants; Humans; Insulin Resistance; Network Meta-Analysis; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Vitamin E | 2018 |
Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults.
Topics: Adult; Diet; Disease Progression; Drug Development; Humans; Life Style; Non-alcoholic Fatty Liver Disease; Pioglitazone; Vitamin E | 2019 |
Role of vitamin E in nonalcoholic fatty liver disease.
Topics: Clinical Trials as Topic; Humans; Insulin Resistance; Liver; Macrophages; Micronutrients; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Vitamin E | 2019 |
Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients.
Topics: Biomarkers; Biopsy; Diagnostic Imaging; Diet; Disease Progression; Humans; Hypoglycemic Agents; Life Style; Liver Transplantation; Non-alcoholic Fatty Liver Disease; Pioglitazone; Vitamin E | 2019 |
Current treatment options for nonalcoholic fatty liver disease.
Topics: Antioxidants; Bariatric Surgery; Chalcones; Chenodeoxycholic Acid; Coffee; Diet, Reducing; Dipeptidyl-Peptidase IV Inhibitors; Exercise; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Receptors, Cytoplasmic and Nuclear; Sleep; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E | 2019 |
Nonalcoholic Fatty Liver Disease and Obesity Treatment.
Topics: Bariatric Surgery; Body Weight; Diet; Exercise; Glucagon-Like Peptide 1; Humans; Inflammation; Insulin Resistance; Liver; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Prostatic Neoplasms; Vitamin E; Weight Loss | 2019 |
Diagnosis and management of non-alcoholic fatty liver disease.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Disease Management; Elasticity Imaging Techniques; Exercise; Humans; Hypoglycemic Agents; Liver; Liver Cirrhosis; Magnetic Resonance Imaging; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Tomography, X-Ray Computed; Ultrasonography; Vitamin E; Weight Reduction Programs | 2019 |
A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH).
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Guidelines as Topic; Humans; Life Style; Non-alcoholic Fatty Liver Disease; Pioglitazone; Vitamin E | 2019 |
Position statement on the diagnosis and management of non-alcoholic fatty liver disease.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Chalcones; Chenodeoxycholic Acid; Diagnostic Imaging; Healthy Lifestyle; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Liver; Liver Transplantation; Mass Screening; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prevalence; Propionates; Thiazolidinediones; Vitamin E | 2019 |
Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
Topics: Bariatric Surgery; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Orlistat; Precision Medicine; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E; Weight Loss | 2014 |
KASL clinical practice guidelines: management of nonalcoholic fatty liver disease.
Topics: Alanine Transaminase; Alcohol Drinking; Antioxidants; Aspartate Aminotransferases; Elasticity Imaging Techniques; Energy Intake; Exercise; Fatty Liver; Humans; Liver Function Tests; Magnetic Resonance Imaging; Non-alcoholic Fatty Liver Disease; Risk Factors; Tomography, X-Ray Computed; Vitamin E | 2013 |
State of the art: treatment of nonalcoholic steatohepatitis.
Topics: Antioxidants; Exercise; Humans; Hypoglycemic Agents; Life Style; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Thiazolidinediones; Vitamin E; Weight Loss | 2014 |
Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
Topics: Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Dietary Supplements; Hepatitis C, Chronic; Humans; Liver; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Vitamin E | 2014 |
Review article: the management of paediatric nonalcoholic fatty liver disease.
Topics: Child; Diet; Humans; Life Style; Motor Activity; Non-alcoholic Fatty Liver Disease; Vitamin E; Weight Loss | 2014 |
Nonalcoholic fatty liver disease: new treatments.
Topics: Antioxidants; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Risk Reduction Behavior; Thiazolidinediones; Vitamin E; Weight Loss | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Liver; Humans; Liver; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Risk Factors; Thiazolidinediones; Vitamin E | 2015 |
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Topics: Anticholesteremic Agents; Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Disease Progression; Genetic Variation; Humans; Hypoglycemic Agents; Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Membrane Proteins; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Obesity, Morbid; Prognosis; Receptors, Cytoplasmic and Nuclear; Vitamin E | 2015 |
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
Topics: Chenodeoxycholic Acid; Drug Therapy, Combination; Humans; Non-alcoholic Fatty Liver Disease; Pioglitazone; Publication Bias; Rosiglitazone; Thiazolidinediones; Vitamin E | 2015 |
Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
Topics: Bariatric Surgery; Diabetes Mellitus; Gastrointestinal Agents; Humans; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Thiazolidinediones; Transaminases; Treatment Outcome; United States; Vitamin E; Vitamins | 2015 |
Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance.
Topics: Caloric Restriction; Dietary Carbohydrates; Dietary Fats; Humans; Insulin Resistance; Liver; Non-alcoholic Fatty Liver Disease; Vitamin E | 2015 |
Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Topics: Antioxidants; Bariatric Surgery; Exercise; Fatty Acids, Omega-6; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Thiazolidinediones; Vitamin E | 2016 |
Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
Topics: Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Anticholesteremic Agents; Antioxidants; Cannabinoid Receptor Antagonists; Cholagogues and Choleretics; Fatty Acids, Omega-3; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metformin; Non-alcoholic Fatty Liver Disease; Orlistat; Pentoxifylline; Piperidines; Probiotics; Pyrazoles; Rimonabant; Synbiotics; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E | 2016 |
Nonalcoholic Fatty Liver Disease and Liver Transplantation.
Topics: Antioxidants; Body Mass Index; Body Weight; Cardiovascular Diseases; Comorbidity; Diet; Humans; Hypoglycemic Agents; Liver Transplantation; Non-alcoholic Fatty Liver Disease; Recurrence; Renal Insufficiency, Chronic; Survival Rate; Vitamin E | 2016 |
Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.
Topics: Antioxidants; Chenodeoxycholic Acid; Humans; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Thiazolidinediones; Treatment Outcome; Vitamin E | 2016 |
Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
Topics: Animals; Antioxidants; Humans; Non-alcoholic Fatty Liver Disease; Vitamin D; Vitamin E; Xanthophylls | 2016 |
Emerging and future therapies for nonalcoholic steatohepatitis in adults.
Topics: Adult; Chenodeoxycholic Acid; Drug Design; Glucagon-Like Peptide 1; Humans; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Thiazolidinediones; Vitamin E | 2016 |
The therapeutic landscape of non-alcoholic steatohepatitis.
Topics: Antioxidants; Chalcones; Chenodeoxycholic Acid; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pioglitazone; Propionates; Randomized Controlled Trials as Topic; Thiazolidinediones; Vitamin E; Weight Loss | 2017 |
Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.
Topics: Biomarkers; Chenodeoxycholic Acid; Clinical Trials as Topic; Fatty Liver; Fibrosis; Humans; Liver; Magnetic Resonance Imaging; Non-alcoholic Fatty Liver Disease; Tomography, X-Ray Computed; Ultrasonography; Vitamin E | 2016 |
Therapies in non-alcoholic steatohepatitis (NASH).
Topics: Carcinoma, Hepatocellular; Diet; Disease Progression; Exercise; Fibrosis; Humans; Hypoglycemic Agents; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Thiazolidinediones; Vitamin E | 2017 |
Nonalcoholic fatty liver disease in children.
Topics: Child; Diet; Exercise; Fatty Liver; Genetic Predisposition to Disease; Humans; Liver Cirrhosis; Magnetic Resonance Imaging; Non-alcoholic Fatty Liver Disease; Obesity; Prevalence; Vitamin E | 2011 |
[Fatty liver and its clinical management in obese adolescents].
Topics: Adiponectin; Adolescent; Apoptosis; Biomarkers; Chemokines; Disease Progression; Fatty Liver; Fibrosis; Hepatocytes; Humans; Hypertriglyceridemia; Insulin Resistance; Kupffer Cells; Liver Cirrhosis; Liver Transplantation; Metformin; Models, Biological; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Ursodeoxycholic Acid; Vitamin E | 2011 |
Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?
Topics: Animals; Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Mitochondria, Liver; Mitochondrial Diseases; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Vitamin E | 2011 |
Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment.
Topics: Diabetes Mellitus, Type 2; Fatty Liver; Humans; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglitazone; Risk Factors; Thiazolidinediones; Treatment Outcome; Vitamin E; Weight Loss | 2011 |
Vitamin E and nonalcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Antioxidants; Diabetes Mellitus; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Liver; Humans; Meta-Analysis as Topic; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones; Treatment Outcome; Vitamin E | 2012 |
Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
Topics: Carcinoma, Hepatocellular; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones; Vitamin E; Weight Loss | 2013 |
39 trial(s) available for d-alpha tocopherol and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: A randomized double-blind active-controlled trial.
Topics: alpha-Tocopherol; Biomarkers; Body Weight; Double-Blind Method; Humans; Inflammation; Insulin Resistance; Liver; Non-alcoholic Fatty Liver Disease; Vitamin E | 2022 |
Hepato-Protective Effects of Delta-Tocotrienol and Alpha-Tocopherol in Patients with Non-Alcoholic Fatty Liver Disease: Regulation of Circulating MicroRNA Expression.
Topics: alpha-Tocopherol; Biomarkers; Circulating MicroRNA; Humans; Inflammation; Insulin Resistance; Liver; MicroRNAs; Non-alcoholic Fatty Liver Disease | 2022 |
Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial.
Topics: Adult; Aged; Alanine Transaminase; alpha-Tocopherol; Apolipoproteins B; Aspartate Aminotransferases; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Liver; Female; gamma-Glutamyltransferase; Humans; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Nutrition Assessment; Prospective Studies; Risk Factors; Tocotrienols; Triglycerides; Ultrasonography | 2013 |
The effects of co-administration of artichoke leaf extract supplementation with metformin and vitamin E in patients with nonalcoholic fatty liver disease: A randomized clinical trial.
Topics: Alanine Transaminase; Cynara scolymus; Dietary Supplements; Humans; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Plant Extracts; Vitamin E | 2021 |
A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients.
Topics: Adult; Antioxidants; Cholagogues and Choleretics; Disease Progression; Egypt; Female; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pentoxifylline; Phosphodiesterase Inhibitors; Prospective Studies; Single-Blind Method; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2021 |
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pioglitazone; Proteomics; Vitamin E | 2023 |
Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Humans; Hypoglycemic Agents; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Vitamin E | 2023 |
Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial.
Topics: Adult; Dietary Supplements; Double-Blind Method; Humans; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Silymarin; Vitamin E | 2023 |
Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients.
Topics: Administration, Oral; Alanine Transaminase; Canada; Coinfection; Female; HIV Infections; Humans; Keratin-18; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Vitamin E | 2020 |
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients.
Topics: Adult; Aged; Biomarkers; Body Weight; Cytokines; Drug Therapy, Combination; Endothelial Cells; Female; Humans; Insulin Resistance; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Silybin; Vitamin D; Vitamin E | 2019 |
Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial.
Topics: Adult; Aged; Biomarkers; Double-Blind Method; Female; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Vitamin E; Young Adult | 2020 |
Antioxidant activity of Hydroxytyrosol and Vitamin E reduces systemic inflammation in children with paediatric NAFLD.
Topics: Antioxidants; Biomarkers; Child; Drug Combinations; Female; Humans; Interleukin-10; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Phenylethyl Alcohol; Vitamin E | 2021 |
Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis- A randomized pilot study.
Topics: Adolescent; Adult; Alanine Transaminase; Antioxidants; Drug Therapy, Combination; Female; Humans; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pilot Projects; Prospective Studies; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Vitamin E; Young Adult | 2021 |
Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin.
Topics: Adolescent; Area Under Curve; Biopsy; Child; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Liver; Liver Cirrhosis; Logistic Models; Male; Metformin; Non-alcoholic Fatty Liver Disease; Odds Ratio; ROC Curve; Severity of Illness Index; Treatment Outcome; Vitamin E; Vitamins | 2021 |
Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.
Topics: Adipokines; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Biopsy; Combined Modality Therapy; Dietary Supplements; Female; Humans; Hyperinsulinism; Insulin Resistance; Intention to Treat Analysis; Liver; Liver Cirrhosis; Male; Mineralocorticoid Receptor Antagonists; Non-alcoholic Fatty Liver Disease; Severity of Illness Index; Spironolactone; Ultrasonography; Vitamin E | 2017 |
Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial.
Topics: Adolescent; Biomarkers; Biopsy; Child; Child Nutritional Physiological Phenomena; Choline; Combined Modality Therapy; Dietary Supplements; Disease Progression; Docosahexaenoic Acids; Double-Blind Method; Exercise; Female; Follow-Up Studies; Healthy Lifestyle; Humans; Liver; Male; Non-alcoholic Fatty Liver Disease; Severity of Illness Index; Vitamin E | 2017 |
Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
Topics: Body Weights and Measures; China; Cytokines; Double-Blind Method; Elasticity Imaging Techniques; Genotype; Haptoglobins; Humans; Inflammation; Life Style; Mobile Applications; Non-alcoholic Fatty Liver Disease; Quality of Life; Research Design; Severity of Illness Index; Vitamin E | 2018 |
Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease.
Topics: Adult; Alanine Transaminase; Anti-Inflammatory Agents; Antioxidants; Aspartate Aminotransferases; Biomarkers; Dietary Supplements; Double-Blind Method; Fatty Liver; Female; Humans; Inflammation; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pilot Projects; Treatment Outcome; Vitamin E | 2018 |
Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.
Topics: Carrier Proteins; Case-Control Studies; Drug Therapy, Combination; Humans; Mineralocorticoid Receptor Antagonists; Non-alcoholic Fatty Liver Disease; Spironolactone; Vitamin E | 2018 |
The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.
Topics: Adiponectin; Adult; Biomarkers; Body Composition; Double-Blind Method; Female; Humans; Inflammation; Interleukin-6; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Thioctic Acid; Vitamin E | 2019 |
The Antioxidant Effects of Hydroxytyrosol and Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease, in a Clinical Trial: A New Treatment?
Topics: Administration, Oral; Adolescent; Child; Double-Blind Method; Female; Glycation End Products, Advanced; Humans; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Phenylethyl Alcohol; Protein Carbonylation; Treatment Outcome; Vitamin E | 2019 |
Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.
Topics: Adult; Biomarkers; Biopsy; Dyslipidemias; E-Selectin; Female; Humans; Intercellular Adhesion Molecule-1; Lipoproteins; Macrophage Activation; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Particle Size; Pioglitazone; Remission Induction; Retrospective Studies; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vitamin E | 2019 |
Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Iran; Lipids; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Risk Reduction Behavior; Silymarin; Time Factors; Treatment Outcome; Vitamin E; Waist Circumference; Young Adult | 2019 |
COMPARATIVE ANALYSIS OF EFFICIENCY OF URSODEOXYCHOLIC ACID AND COMBINATION OF VITAMIN E AND VITAMIN C IN TREATMENT OF NON-DIABETIC NONALCOHOLIC STEATOHEPATITIS.
Topics: Antioxidants; Ascorbic Acid; Humans; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2019 |
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Adult; Biopsy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Inflammation; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Proof of Concept Study; Treatment Outcome; Vitamin E; Vitamins | 2019 |
Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Antioxidants; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones; Vitamin E; Weight Loss | 2013 |
Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose.
Topics: Alanine Transaminase; Biphenyl Compounds; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Liver; Male; Metformin; Non-alcoholic Fatty Liver Disease; Vitamin E | 2014 |
Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Cross-Sectional Studies; Female; Fibrosis; Hedgehog Proteins; Hepatocytes; Humans; Immunohistochemistry; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Vitamin E; Vitamins | 2015 |
NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Humans; Lipoproteins, HDL; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Risk; Thiazolidinediones; Triglycerides; Vitamin E | 2015 |
Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease.
Topics: Adult; Biomarkers; Body Mass Index; Cholesterol; Diet, Mediterranean; Dietary Supplements; Humans; Italy; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Overweight; Phosphatidylcholines; Prospective Studies; Silybin; Silymarin; Time Factors; Treatment Outcome; Triglycerides; Vitamin E; Waist Circumference | 2015 |
Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study.
Topics: Adult; Aged; Antioxidants; Combined Modality Therapy; Dietary Supplements; Drug Combinations; Female; Humans; Life Style; Male; Metabolic Syndrome; Middle Aged; Non-alcoholic Fatty Liver Disease; Silymarin; Treatment Outcome; Vitamin E | 2015 |
Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pilot Projects; Silymarin; Vitamin E; Young Adult | 2015 |
Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Body Weight; Cohort Studies; Female; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Male; Metabolic Syndrome; Middle Aged; Non-alcoholic Fatty Liver Disease; Propensity Score; Republic of Korea; Retrospective Studies; Vitamin E | 2015 |
[COMPARISON OF DIFFERENT TREATMENT REGIMENS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE].
Topics: Adult; Aged; Atorvastatin; Female; Humans; Interleukin-6; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Tumor Necrosis Factor-alpha; Ursodeoxycholic Acid; Vitamin E | 2015 |
Conjugated linoleic acid improves glycemic response, lipid profile, and oxidative stress in obese patients with non-alcoholic fatty liver disease: a randomized controlled clinical trial.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Body Weights and Measures; Diet, Reducing; Female; Glycated Hemoglobin; Humans; Insulin Resistance; Linoleic Acids, Conjugated; Lipids; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Vitamin E | 2016 |
Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease.
Topics: Animals; Fatty Liver; Female; Humans; Insulin Resistance; Male; Mice; Middle Aged; Mineralocorticoid Receptor Antagonists; Non-alcoholic Fatty Liver Disease; Spironolactone; Vitamin E | 2011 |
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.
Topics: Adolescent; Alanine Transaminase; Antioxidants; Child; Double-Blind Method; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Metformin; Non-alcoholic Fatty Liver Disease; Obesity; Severity of Illness Index; Treatment Outcome; Vitamin E | 2011 |
Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
Topics: Adipose Tissue; Adult; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Liver; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Reference Values; Thiazolidinediones; Time Factors; Treatment Outcome; Vitamin E | 2012 |
Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Antioxidants; Aspartate Aminotransferases; Bilirubin; Biomarkers; Blood Glucose; Blood Pressure; Chi-Square Distribution; Chlorella vulgaris; Drug Therapy, Combination; Fatty Liver; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Iran; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Plant Preparations; Serum Albumin; Serum Albumin, Human; Time Factors; Treatment Outcome; Triglycerides; Uric Acid; Vitamin E; Weight Loss | 2012 |
88 other study(ies) available for d-alpha tocopherol and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
Topics: Animals; Body Weight; Carbon Tetrachloride; Dose-Response Relationship, Drug; Drug Design; Fibrosis; Humans; Inflammation; Liver; Mice; Molecular Structure; Non-alcoholic Fatty Liver Disease; Organ Size; Peptides, Cyclic; Prodrugs; Structure-Activity Relationship; Vitamin E | 2022 |
Cholesterol accumulation in hepatocytes mediates IRE1/p38 branch of endoplasmic reticulum stress to promote nonalcoholic steatohepatitis.
Topics: alpha-Tocopherol; Animals; Apoptosis; Cholesterol; Endoplasmic Reticulum Stress; Hepatocytes; Liposomes; Liver; Non-alcoholic Fatty Liver Disease; Protein Serine-Threonine Kinases; Rabbits | 2022 |
Treatment of Non-Alcoholic Steatosis: Preclinical Study of a New Nutraceutical Multitarget Formulation.
Topics: alpha-Tocopherol; Animals; Anti-Inflammatory Agents; Antioxidants; Cells, Cultured; Chlorogenic Acid; Choline; Coffee; Dietary Supplements; Disease Models, Animal; Docosahexaenoic Acids; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oleic Acid; Plant Extracts; Silybum marianum; Tanacetum parthenium | 2020 |
Dynamics of Serum Retinol and Alpha-Tocopherol Levels According to Non-Alcoholic Fatty Liver Disease Status.
Topics: Adult; alpha-Tocopherol; Cross-Sectional Studies; Female; Fibrosis; Humans; Male; Micronutrients; Middle Aged; Non-alcoholic Fatty Liver Disease; Nutrition Surveys; Republic of Korea; Vitamin A; Vitamin A Deficiency; Vitamin E; Vitamins | 2021 |
alpha-Tocopherol supplementation reduces inflammation and apoptosis in high cholesterol mediated nonalcoholic steatohepatitis.
Topics: alpha-Tocopherol; Animals; Antioxidants; Apoptosis; Dietary Supplements; Disease Models, Animal; Hypercholesterolemia; Inflammation; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rabbits | 2021 |
Nonalcoholic fatty liver disease impairs the cytochrome P-450-dependent metabolism of α-tocopherol (vitamin E).
Topics: alpha-Tocopherol; Animals; Cytochrome P450 Family 4; Diet, Carbohydrate Loading; Diet, High-Fat; Diet, Western; Fatty Acids, Nonesterified; Fructose; Gene Expression Regulation; Hep G2 Cells; Humans; Hydroxylation; Liver; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oleic Acid; Palmitic Acid; PPAR gamma; Sterol Regulatory Element Binding Protein 1 | 2017 |
Association of Vitamin E Levels with Metabolic Syndrome, and MRI-Derived Body Fat Volumes and Liver Fat Content.
Topics: Adiposity; Aged; alpha-Tocopherol; Biomarkers; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Female; gamma-Tocopherol; Germany; Humans; Intra-Abdominal Fat; Linear Models; Liver; Logistic Models; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Odds Ratio; Predictive Value of Tests; Vitamin E | 2017 |
Increased plasma levels of the lipoperoxyl radical-derived vitamin E metabolite α-tocopheryl quinone are an early indicator of lipotoxicity in fatty liver subjects.
Topics: Adult; Alanine Transaminase; Aldehydes; alpha-Tocopherol; Bilirubin; Cholesterol, LDL; Cross-Sectional Studies; Fatty Acids, Unsaturated; Female; Free Radical Scavengers; Gas Chromatography-Mass Spectrometry; Hepatocytes; Humans; Lipid Peroxidation; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pilot Projects; Triglycerides; Vitamin E | 2019 |
Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials.
Topics: alpha-Tocopherol; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Gene Frequency; Genotype; Humans; Non-alcoholic Fatty Liver Disease; Polymorphism, Genetic; Vitamin E | 2014 |
[EFFECTS OF MELATONIN ON THE ACONITATE HYDRATASE ACTIVITY, CONTENT OF LIPID PEROXIDATION PRODUCTS AND SOME NON-ENZYMATIC ANTIOXIDANTS IN THE BLOOD OF PATIENTS WITH TYPE 2 DIABETES MELLITUS COMPLICATED BY STEATOHEPATITIS].
Topics: Aconitate Hydratase; Adult; Aged; alpha-Tocopherol; Antioxidants; Citric Acid; Diabetes Mellitus, Type 2; Female; Humans; Lipid Peroxidation; Liver; Male; Malondialdehyde; Melatonin; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxidative Stress | 2015 |
Dietary α- and γ-tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis.
Topics: Alanine Transaminase; alpha-Tocopherol; Animals; Antioxidants; Body Weight; Dietary Supplements; Fatty Liver; gamma-Tocopherol; Inflammation; Lipid Peroxidation; Lipopolysaccharides; Liver; Male; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Triglycerides | 2010 |
Role of vitamin E in the treatment of non-alcoholic steatohepatitis.
Topics: Antifibrotic Agents; Carcinoma, Hepatocellular; Humans; Liver; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Vitamin E | 2021 |
Platelet-neutrophil hybrid membrane-coated gelatin nanoparticles for enhanced targeting ability and intelligent release in the treatment of non-alcoholic steatohepatitis.
Topics: Animals; Gelatin; Liver; Nanoparticles; Neutrophils; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rats; Vitamin E | 2022 |
Dietary Vitamin E Intake Is Associated With a Reduced Risk of Developing Digestive Diseases and Nonalcoholic Fatty Liver Disease.
Topics: Diet; Humans; Non-alcoholic Fatty Liver Disease; Nutritional Status; Vitamin E | 2022 |
Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life.
Topics: Fibrosis; Humans; Ligands; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Patient Reported Outcome Measures; Pioglitazone; Quality of Life; Vitamin E | 2022 |
Combination Treatment with Hydroxytyrosol and Vitamin E Improves NAFLD-Related Fibrosis.
Topics: Animals; Carbon Tetrachloride; Fibrosis; Liver; Liver Cirrhosis; Mice; Non-alcoholic Fatty Liver Disease; Phenylethyl Alcohol; Reactive Oxygen Species; Transcription Factors; Transforming Growth Factor beta; Vitamin E | 2022 |
[The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities].
Topics: Adult; Anti-Inflammatory Agents; Anticarcinogenic Agents; Antioxidants; Diabetes Mellitus, Type 2; Glucose; Humans; Inflammation; Lipids; Liver; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E | 2022 |
Ornithine Aspartate and Vitamin-E Combination Has Beneficial Effects on Cardiovascular Risk Factors in an Animal Model of Nonalcoholic Fatty Liver Disease in Rats.
Topics: Animals; Cardiovascular Diseases; Dipeptides; Disease Models, Animal; Drug Therapy, Combination; Liver; MicroRNAs; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Risk Factors; Vitamin E | 2022 |
Comparative effects of thymol and vitamin E on nonalcoholic fatty liver disease in male Wistar rats.
Topics: Animals; Antioxidants; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Thymol; Vitamin E | 2023 |
Aerobic exercise and vitamin E improve high-fat diet-induced NAFLD in rats by regulating the AMPK pathway and oxidative stress.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Lipid Metabolism; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats; Vitamin E | 2023 |
Ability of high fat diet to induce liver pathology correlates with the level of linoleic acid and Vitamin E in the diet.
Topics: Animals; Diet, High-Fat; Fatty Acids, Nonesterified; Fatty Acids, Unsaturated; Linoleic Acid; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Triglycerides; Vitamin E | 2023 |
Asporin levels are low in patients with nonalcoholic fatty liver disease and increase after vitamin E treatment.
Topics: Alanine Transaminase; Humans; Non-alcoholic Fatty Liver Disease; Vitamin E | 2019 |
Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Atorvastatin; Caloric Restriction; Combined Modality Therapy; Female; Guinea Pigs; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Liver; Liver Cirrhosis, Experimental; Non-alcoholic Fatty Liver Disease; Time Factors; Vitamin E | 2019 |
Vitamin E as a 'bridge' therapy for nonalcoholic steatohepatits in HIV: what is waiting on the other side of the bridge?
Topics: HIV Infections; Humans; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Vitamin E | 2020 |
Identifying Predictors of Response to Vitamin E for the Treatment of Pediatric Nonalcoholic Steatohepatitis.
Topics: Alanine Transaminase; Biopsy; Child; Humans; Liver; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Vitamin E | 2020 |
Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis.
Topics: Adult; Aspartate Aminotransferases; Biomarkers; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Severity of Illness Index; Vitamin E | 2021 |
4-HNE Immunohistochemistry and Image Analysis for Detection of Lipid Peroxidation in Human Liver Samples Using Vitamin E Treatment in NAFLD as a Proof of Concept.
Topics: Aldehydes; Antioxidants; Cells, Cultured; Humans; Immunohistochemistry; Lipid Peroxidation; Liver; Non-alcoholic Fatty Liver Disease; Optical Imaging; Vitamin E | 2020 |
Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis.
Topics: Humans; Lipogenesis; Liver; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Up-Regulation; Vitamin E | 2020 |
Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients.
Topics: Ascorbic Acid; Diet, Reducing; Humans; Lipids; Liver; Non-alcoholic Fatty Liver Disease; Obesity; Selenomethionine; Silymarin; Ubiquinone; Vitamin E | 2020 |
Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Bariatric Surgery; Biopsy; Diet, Reducing; Elasticity Imaging Techniques; Exercise; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liver; Liver Cirrhosis; Magnetic Resonance Imaging; Non-alcoholic Fatty Liver Disease; Referral and Consultation; Risk Assessment; Serum Albumin; Severity of Illness Index; Thiazolidinediones; Vitamin E; Vitamins | 2020 |
The Effects of Vitamin E, Silymarin and Carnitine on the Metabolic Abnormalities Associated with Nonalcoholic Liver Disease.
Topics: Blood Glucose; Carnitine; Glucose; Humans; Insulin; Insulin Resistance; Liver; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Silymarin; Triglycerides; Vitamin E | 2022 |
Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver-Related Events in Nonalcoholic Fatty Liver Disease.
Topics: Adult; Bile Acids and Salts; Biomarkers; Female; Follow-Up Studies; Humans; Linear Models; Male; Metabolomics; Middle Aged; Non-alcoholic Fatty Liver Disease; Proportional Hazards Models; Risk Factors; Serotonin; Vitamin E | 2021 |
Tocopheryl quinone improves non-alcoholic steatohepatitis (NASH) associated dysmetabolism of glucose and lipids by upregulating the expression of glucagon-like peptide 1 (GLP-1)
Topics: Animals; Antioxidants; Diet, High-Fat; Disease Models, Animal; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Glucose; Lipid Metabolism; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats; Rats, Sprague-Dawley; Up-Regulation; Vitamin E | 2021 |
Management of Pediatric Nonalcoholic Fatty Liver Disease by Academic Hepatologists in Canada: A Nationwide Survey.
Topics: Academic Medical Centers; Canada; Child; Combined Modality Therapy; Diet Therapy; Exercise Therapy; Gastroenterology; Health Care Surveys; Health Promotion; Healthcare Disparities; Humans; Non-alcoholic Fatty Liver Disease; Pediatrics; Practice Patterns, Physicians'; Vitamin E; Vitamins | 2017 |
Treatment of NASH: What Helps Beyond Weight Loss?
Topics: Alcohol Drinking; Comorbidity; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Humans; Hypoglycemic Agents; Liver Function Tests; Non-alcoholic Fatty Liver Disease; Patient Care Planning; Pioglitazone; Prognosis; Risk Assessment; Risk Factors; Vitamin E; Weight Loss | 2017 |
Letter to the Editor: Bioinformatics Analysis in Mice with Diet-Induced Nonalcoholic Steatohepatitis Treated with Astaxanthin and Vitamin E.
Topics: Animals; Computational Biology; Diet; Disease Models, Animal; Liver; Mice; Non-alcoholic Fatty Liver Disease; Transcriptome; Vitamin E; Xanthophylls | 2017 |
Reply to the Letter to the Editor by Li et al.: Bioinformatics Analysis in Mice with Diet-Induced Nonalcoholic Steatohepatitis Treated with Astaxanthin and Vitamin E.
Topics: Animals; Computational Biology; Diet; Insulin Resistance; Mice; Non-alcoholic Fatty Liver Disease; Vitamin E; Xanthophylls | 2017 |
Effects of delta-tocotrienol on obesity-related adipocyte hypertrophy, inflammation and hepatic steatosis in high-fat-fed mice.
Topics: Adipocytes; Adipose Tissue, White; Animals; Body Weight; Diet, High-Fat; Lipid Metabolism; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Panniculitis; Triglycerides; Vitamin E | 2017 |
Short-term vitamin E treatment impairs reactive oxygen species signaling required for adipose tissue expansion, resulting in fatty liver and insulin resistance in obese mice.
Topics: Adipogenesis; Adipose Tissue; Animals; Body Weight; Diet, High-Fat; Hepatomegaly; Insulin Resistance; Intra-Abdominal Fat; Male; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Reactive Oxygen Species; Signal Transduction; Time Factors; Vitamin E | 2017 |
Association of vitamin E intake at early childhood with alanine aminotransferase levels at mid-childhood.
Topics: Alanine Transaminase; Body Mass Index; Child; Child, Preschool; Cohort Studies; Female; Humans; Male; Non-alcoholic Fatty Liver Disease; Prospective Studies; Vitamin E | 2018 |
Hepatic accumulation of S-adenosylmethionine in hamsters with non-alcoholic fatty liver disease associated with metabolic syndrome under selenium and vitamin E deficiency.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Cricetinae; Diet, High-Fat; Disease Progression; Humans; Liver; Male; Mesocricetus; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Oncogene Protein p55(v-myc); Protein Kinases; S-Adenosylmethionine; Selenium; Vitamin E | 2019 |
Swimming, but not vitamin E, ameliorates prothrombotic state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Biomarkers; Blood Coagulation; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Diet, High-Fat; Fibrinolysis; Insulin; Insulin Resistance; Lipids; Liver; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Rats; Rats, Sprague-Dawley; Risk Factors; Swimming; Triglycerides; Vitamin E | 2018 |
Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease.
Topics: Antioxidants; Drug Combinations; Female; Humans; Lipase; Male; Membrane Proteins; Middle Aged; Non-alcoholic Fatty Liver Disease; Pilot Projects; Polymorphism, Genetic; Prospective Studies; Silymarin; Treatment Outcome; Vitamin E | 2018 |
Gamma-Tocotrienol Attenuates the Hepatic Inflammation and Fibrosis by Suppressing Endoplasmic Reticulum Stress in Mice.
Topics: Animals; Body Weight; Cholesterol; Chromans; Diet, Western; Dietary Supplements; Endoplasmic Reticulum Stress; Fibrosis; Hepatitis; Insulin Resistance; Liver; Male; Methionine; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Triglycerides; Vitamin E | 2018 |
Vitamin E - a cause for concern?
Topics: Humans; Non-alcoholic Fatty Liver Disease; Vitamin E | 2018 |
Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand.
Topics: Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Hypoglycemic Agents; Liver Cirrhosis; Liver Neoplasms; Markov Chains; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Quality-Adjusted Life Years; Thailand; Vitamin E; Weight Loss; Weight Reduction Programs | 2019 |
Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis.
Topics: Disease-Free Survival; Female; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Severity of Illness Index; Vitamin E; Vitamins | 2020 |
Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Topics: Adult; Biopsy; Chenodeoxycholic Acid; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Retrospective Studies; Treatment Outcome; Vitamin E; Vitamins | 2019 |
Non-alcoholic steatohepatitis associated with Netherton syndrome.
Topics: Alanine Transaminase; Dietary Supplements; Humans; Male; Netherton Syndrome; Non-alcoholic Fatty Liver Disease; Vitamin E; Vitamins; Young Adult | 2018 |
THE EFFECT OF APPLICATION OF ANTIOXIDANT THERAPY IN THE TREATMENT OF NON-ALKOHOLIC STEATOHEPATATIS IN CHORNOBYL NPP ACCIDENT SUFFERERS IN THE REMOTE PERIOD AFTER IRRADIATION.
Topics: Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Catalase; Chernobyl Nuclear Accident; Emergency Responders; Environmental Exposure; Female; gamma-Glutamyltransferase; Humans; Hypercholesterolemia; Hyperglycemia; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Radiation Dosage; Radiation Exposure; Radiation, Ionizing; Superoxide Dismutase; Transportation of Patients; Ukraine; Ultrasonography; Vitamin A; Vitamin E | 2018 |
Nutritional and lipidomics biomarkers of docosahexaenoic acid-based multivitamin therapy in pediatric NASH.
Topics: Adolescent; alpha-Linolenic Acid; Arachidonic Acid; Biomarkers; Child; Choline; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Humans; Lipid Metabolism; Lipidomics; Liver; Male; Non-alcoholic Fatty Liver Disease; Vitamin D; Vitamin E; Vitamins | 2019 |
Reply.
Topics: Fibrosis; Humans; Non-alcoholic Fatty Liver Disease; Vitamin E | 2019 |
Letter to the Editor: Will Vitamin E Be the Hope of Patients With NASH and Advanced Fibrosis? The Reliability Is Worth Discussing.
Topics: Fibrosis; Humans; Non-alcoholic Fatty Liver Disease; Reproducibility of Results; Vitamin E | 2019 |
Vitamin E Ameliorates Lipid Metabolism in Mice with Nonalcoholic Fatty Liver Disease via Nrf2/CES1 Signaling Pathway.
Topics: Animals; Antioxidants; Carboxylic Ester Hydrolases; Glucose; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Non-alcoholic Fatty Liver Disease; Signal Transduction; Vitamin E | 2019 |
Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease.
Topics: Antioxidants; Ascorbic Acid; Correlation of Data; Cross-Sectional Studies; Diet; Female; Humans; Israel; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Nutrition Assessment; Protective Factors; Severity of Illness Index; Ultrasonography; Vitamin E | 2019 |
Long-term (>=2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Antioxidants; Fatty Liver; Female; Humans; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Time Factors; Vitamin E | 2013 |
A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls.
Topics: Adult; Aged; Ascorbic Acid; Body Mass Index; Canada; Case-Control Studies; Cross-Sectional Studies; Diet Records; Dietary Fats; Energy Intake; Fatty Liver; Female; Guidelines as Topic; Healthy Volunteers; Humans; Insulin Resistance; Male; Middle Aged; Motor Activity; Non-alcoholic Fatty Liver Disease; Nutrition Assessment; Prospective Studies; Sodium, Dietary; Vitamin D; Vitamin E; Young Adult | 2014 |
Ballooned hepatocytes, undead cells, sonic hedgehog, and vitamin E: therapeutic implications for nonalcoholic steatohepatitis.
Topics: Female; Hedgehog Proteins; Humans; Male; Non-alcoholic Fatty Liver Disease; Vitamin E; Vitamins | 2015 |
Reply: To PMID 24849310.
Topics: Female; Hedgehog Proteins; Humans; Male; Non-alcoholic Fatty Liver Disease; Vitamin E; Vitamins | 2015 |
GLI2 as a marker of hedgehog-responsive cells.
Topics: Female; Hedgehog Proteins; Humans; Male; Non-alcoholic Fatty Liver Disease; Vitamin E; Vitamins | 2015 |
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Topics: Bariatric Surgery; Evidence-Based Medicine; Humans; Life Style; Liver Transplantation; Non-alcoholic Fatty Liver Disease; Prevalence; Thiazolidinediones; Vitamin E | 2015 |
Vitamin E therapy for NAFLD/NASH.
Topics: Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Dietary Supplements; Hepatitis C, Chronic; Humans; Non-alcoholic Fatty Liver Disease; Vitamin E | 2015 |
Vitamin E therapy on aminotransferase levels in NAFLD/NASH patients.
Topics: Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Dietary Supplements; Hepatitis C, Chronic; Humans; Non-alcoholic Fatty Liver Disease; Vitamin E | 2015 |
The fat droplet in hepatocellular ballooning and implications for scoring nonalcoholic steatohepatitis therapeutic response.
Topics: Animals; Carotid Artery Diseases; Fatty Liver; Female; Hedgehog Proteins; Humans; Lipase; Lipoproteins, VLDL; Liver; Male; Membrane Proteins; Non-alcoholic Fatty Liver Disease; Vitamin E; Vitamins | 2016 |
Reply.
Topics: Female; Hedgehog Proteins; Humans; Male; Non-alcoholic Fatty Liver Disease; Vitamin E; Vitamins | 2016 |
Effect of anti-oxidant agents in patients with hepatocellular diseases.
Topics: Female; Humans; Male; Non-alcoholic Fatty Liver Disease; Silymarin; Vitamin E | 2015 |
Reply to the Letter "Effect of anti-oxidant agents in patients with hepatocellular diseases".
Topics: Female; Humans; Male; Non-alcoholic Fatty Liver Disease; Silymarin; Vitamin E | 2015 |
Vitamin E Attenuates the Progression of Non-Alcoholic Fatty Liver Disease Caused by Partial Hepatectomy in Mice.
Topics: Animal Feed; Animals; Choline Deficiency; Diet; Disease Models, Animal; Disease Progression; Hepatectomy; Lipid Peroxidation; Liver Regeneration; Male; Mice; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Vitamin E | 2015 |
Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E.
Topics: Animals; Antioxidants; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Diet, High-Fat; Disease Models, Animal; Female; Glucose Metabolism Disorders; Humans; Insulin Resistance; Kupffer Cells; Lipid Peroxidation; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Sterol Regulatory Element Binding Protein 1; Vitamin E; Xanthophylls | 2015 |
Enrolling Research Participants in Private Practice: Conflicts of Interest, Consistency, Therapeutic Misconception, and Informed Consent.
Topics: Ascorbic Acid; Bias; Conflict of Interest; Humans; Informed Consent; Non-alcoholic Fatty Liver Disease; Patient Selection; Private Practice; Randomized Controlled Trials as Topic; Therapeutic Misconception; Treatment Outcome; United States; Vitamin E; Vitamins; Weight Loss | 2015 |
Euterpe edulis Extract but Not Oil Enhances Antioxidant Defenses and Protects against Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet in Rats.
Topics: Animals; Antioxidants; Biomarkers; Diet, High-Fat; Euterpe; Fatty Acids; Freeze Drying; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Phytochemicals; Plant Extracts; Plant Oils; Protective Agents; Rats, Wistar; Vitamin E | 2016 |
Role of oxidative stress and insulin resistance in disease severity of non-alcoholic fatty liver disease.
Topics: Adult; Ascorbic Acid; Female; Glutathione; Humans; Insulin; Insulin Resistance; Liver; Male; Malondialdehyde; Middle Aged; Nitric Oxide; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Severity of Illness Index; Superoxide Dismutase; Vitamin E | 2016 |
Hepatic Transcriptome Profiles of Mice with Diet-Induced Nonalcoholic Steatohepatitis Treated with Astaxanthin and Vitamin E.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Eukaryotic Initiation Factor-2; Gene Expression Profiling; Liver; Male; Mice; Mitochondria; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR delta; Protein Interaction Mapping; Protein Interaction Maps; Retinoic Acid Receptor alpha; Signal Transduction; Transcriptome; Vitamin E; Xanthophylls | 2017 |
On the mechanism of action of vitamin E for nonalcoholic steatohepatitis.
Topics: Antioxidants; Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Vitamin E | 2011 |
Genistein improves liver function and attenuates non-alcoholic fatty liver disease in a rat model of insulin resistance.
Topics: Animals; Ascorbic Acid; Body Weight; Cholesterol; Fatty Liver; Genistein; Glutathione Peroxidase; Glutathione Reductase; Insulin; Insulin Resistance; Interleukin-6; Liver; Liver Function Tests; Male; Non-alcoholic Fatty Liver Disease; Organ Size; Phospholipids; Phytoestrogens; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha; Vitamin E | 2009 |
[Influence of genipin and vitamin E on UCP2 and other correlation factors in non-alcoholic fatty liver disease].
Topics: Cell Line; Drug Synergism; Fatty Liver; Humans; Ion Channels; Iridoid Glycosides; Iridoids; Liver; Membrane Potential, Mitochondrial; Mitochondrial Proteins; NF-kappa B; Non-alcoholic Fatty Liver Disease; Protective Agents; RNA, Messenger; Tumor Necrosis Factor-alpha; Uncoupling Protein 2; Vitamin E | 2010 |
Does vitamin E cure nonalcoholic steatohepatitis?
Topics: Dietary Supplements; Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Vitamin E | 2011 |
Nonalcoholic fatty liver disease: Targeted therapy in children--what is the right way?
Topics: Adolescent; Alanine Transaminase; Child; Fatty Liver; Humans; Life Style; Metformin; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Vitamin E | 2011 |
Vitamin E for nonalcoholic fatty liver disease.
Topics: Animals; Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Obesity; Vitamin E; Vitamins | 2011 |
Medical therapy for nonalcoholic fatty liver disease in children and adolescents.
Topics: Adolescent; Biopsy; Child; Fatty Liver; Humans; Hypoglycemic Agents; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Vitamin E; Vitamins | 2012 |
Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Fatty Liver; Humans; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Time Factors; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E; Vitamins; Young Adult | 2012 |
Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD.
Topics: Adolescent; Ascorbic Acid; Child; Cross-Sectional Studies; Diet; Dietary Sucrose; Energy Intake; Fatty Liver; Female; Fructose; Humans; Liver; Male; Non-alcoholic Fatty Liver Disease; Nutrition Assessment; Prospective Studies; Surveys and Questionnaires; Uric Acid; Vitamin E; Vitamin E Deficiency; Vitamins | 2012 |
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Factors; Thiazolidinediones; Vitamin E | 2012 |
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
Topics: Alcohol Drinking; Bariatric Surgery; Biopsy; Child; Disease Management; Fatty Liver; Fatty Liver, Alcoholic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incidence; Liver Cirrhosis; Mass Screening; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Factors; Risk Reduction Behavior; Severity of Illness Index; United States; Vitamin E; Weight Loss | 2012 |
Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver.
Topics: Adiponectin; Adolescent; Cholesterol, LDL; Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Non-alcoholic Fatty Liver Disease; Obesity; Tumor Necrosis Factor-alpha; Vitamin E | 2011 |
Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis.
Topics: Combined Modality Therapy; Cost-Benefit Analysis; Fatty Liver; Humans; Hypoglycemic Agents; Life Style; Liver Cirrhosis; Markov Chains; Non-alcoholic Fatty Liver Disease; Pioglitazone; Quality-Adjusted Life Years; Severity of Illness Index; Thiazolidinediones; Vitamin E; Vitamins | 2012 |
Metabolomic profiling to identify predictors of response to vitamin E for non-alcoholic steatohepatitis (NASH).
Topics: Adult; Biomarkers; Fatty Liver; Female; Humans; Male; Metabolome; Metabolomics; Middle Aged; Non-alcoholic Fatty Liver Disease; Prognosis; Treatment Outcome; Vitamin E | 2012 |
Bibliography. Micronutrients. Current world literature.
Topics: Calcium, Dietary; Dietary Supplements; Fatty Liver; Fractures, Bone; Humans; Inflammation; Inflammatory Bowel Diseases; Iron; Micronutrients; Non-alcoholic Fatty Liver Disease; Nutritional Physiological Phenomena; Trace Elements; Vitamin D; Vitamin E; Vitamin K | 2012 |